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As the second dimension to the genome, the epigenome contains key information specific to every
type of cells. Thousands of human epigenomemaps have been produced in recent years thanks to
rapid development of high throughput epigenomemapping technologies. In this review, we discuss
the current epigenome mapping toolkit and utilities of epigenome maps. We focus particularly on
mapping of DNAmethylation, chromatin modification state, and chromatin structures, and empha-
size the use of epigenomemaps to delineate human gene regulatory sequences and developmental
programs. We also provide a perspective on the progress of the epigenomics field and challenges
ahead.Introduction
More than a decade has passed since the human genome was
completely sequenced, but how genomic information directs
spatial- and temporal-specific gene expression programs re-
mains to be elucidated (Lander, 2011). The answer to this ques-
tion is not only essential for understanding the mechanisms of
human development, but also key to studying the phenotypic
variations among human populations and the etiology of many
human diseases. However, a major challenge remains: each of
the more than 200 different cell types in the human body con-
tains an identical copy of the genome but expresses a distinct
set of genes. How does a genome guide a limited set of genes
to be expressed at different levels in distinct cell types?
Overwhelming evidence now indicates that the epigenome
serves to instruct the unique gene expression program in each
cell type together with its genome. The word ‘‘epigenetics,’’
coined half a century ago by combining ‘‘epigenesis’’ and ‘‘ge-
netics,’’ describes the mechanisms of cell fate commitment
and lineage specification during animal development (Holliday,
1990; Waddington, 1959). Today, the ‘‘epigenome’’ is generally
used to describe the global, comprehensive view of sequence-
independent processes that modulate gene expression patterns
in a cell and has been liberally applied in reference to the collec-
tion of DNA methylation state and covalent modification of his-
tone proteins along the genome (Bernstein et al., 2007; Bonasio
et al., 2010). The epigenome can differ from cell type to cell type,
and in each cell it regulates gene expression in a number of
ways—by organizing the nuclear architecture of the chromo-
somes, restricting or facilitating transcription factor access to
DNA, and preserving a memory of past transcriptional activities.
Thus, the epigenome represents a second dimension of the
genomic sequence and is pivotal for maintaining cell-type-
specific gene expression patterns.
Not long ago, there were many points of trepidation about
the value and utility of mapping epigenomes in human cells(Madhani et al., 2008). At the time, it was suggested that histone
modifications simply reflect activities of transcription factors
(TFs), so cataloging their patterns would offer little new informa-
tion. However, some investigators believed in the value of epige-
nome maps and advocated for concerted efforts to produce
such resources (Feinberg, 2007; Henikoff et al., 2008; Jones
and Martienssen, 2005). The last five years have shown that
epigenome maps can greatly facilitate the identification of
potential functional sequences and thereby annotation of the
human genome. Now, we appreciate the utility of epigenomic
maps in the delineation of thousands of lincRNA genes and
hundreds of thousands of cis-regulatory elements (ENCODE
Project Consortium et al., 2012; Ernst et al., 2011; Guttman
et al., 2009; Heintzman et al., 2009; Xie et al., 2013b; Zhu
et al., 2013), all of which were obtained without prior knowledge
of cell-type-specific master transcriptional regulators. Interest-
ingly, bioinformatic analysis of tissue-specific cis-regulatory
elements has actually uncovered novel TFs regulating specific
cellular states.
Propelled by rapid technological advances, the field of epige-
nomics is enjoying unprecedented growth with no sign of decel-
eration. An expanding cadre of researchers is working to explore
exciting frontiers in epigenomics. Many international consortia
have been formed to tackle the fundamental problems in epige-
nomics by sharing resources and protocols (Table 1) (Beck et al.,
2012; Bernstein et al., 2010). Consequently, the number of
epigenomic data sets and publications has grown exponentially
in recent years. The resulting epigenomic maps have linked
genomic sequences to many nuclear processes including
splicing, replication, DNA damage response, folding, chromatin
packaging, and cell-type-specific gene expression patterns.
In this review, we focus on recent progress in several areas of
epigenomics (Table 2). First, we describe the remarkable
advances in epigenomic technologies, especially next-genera-
tion sequencing-based applications, which have fueled theCell 155, September 26, 2013 ª2013 Elsevier Inc. 39
Table 1. Large-Scale National and International Epigenomic Consortia
Project Name
Start
Date Affiliations
Completed and Expected
Data Contributions Selected Publication Access Data
Encyclopedia of
DNA Elements
2003 NIH Dnase-seq, RNA-seq,
ChIP-seq, and 5C in 100s
of primary human tissues
and cell lines
ENCODE Project
Consortium et al., 2012
http://encodeproject.org/ENCODE/
The Cancer
Genome Atlas
(TCGA)
2006 NIH DNA methylomes in 1,000s
of patients samples from
more than 20 cancer types
Garraway and Lander,
2013
http://cancergenome.nih.gov/
Roadmap
Epigenomics
Project
2008 NIH Dnase-seq, RNA-seq,
ChIP-seq, and MethylC-seq
in 100 s of normal primary
cells, hESC, and hESC
derived cells
Bernstein et al., 2010 http://www.epigenomebrowser.org/
International
Cancer Genome
Consortium (ICGC)
2008 15 countries,
includes TCGA
DNA methylation profiles in
thousands of patient samples
from 50 different cancers
The International Cancer
Genome Consortium,
et al., 2010
http://dcc.icgc.org/web
International
Human Epigenome
Consortium (IHEC)
2010 7 countries,
includes
BLUEPRINT,
Roadmap
Goal: 1,000 Epigenomes
in 250 cell types
American Association for
Cancer Research Human
Epigenome Task Force;
European Union, Network
of Excellence, Scientific
Advisory Board, 2008
http://ihec-epigenomes.orggrowth of the field. Second, we discuss the utility of epigenomic
maps, emphasizing the power of these maps in annotating tran-
scription units and cis-regulatory elements in the context of
development and disease pathogenesis. We also explore new
biological insights gained through integrative analysis of epige-
nomic maps in mammalian cell systems, highlighting the study
of pluripotency and lineage specification of embryonic stem
cells. Finally, we provide a perspective on the road ahead
regarding meeting the technical challenges and addressing
unanswered questions in the field. As for advancements in our
understanding of the mechanistic roles of sequence-specific
TFs and noncoding RNAs, chromatin, DNA modifying enzymes,
and chromatin-binding proteins in establishing, maintaining, and
removing epigenetic marks, we refer readers to recent excellent
reviews (Badeaux and Shi, 2013; Calo and Wysocka, 2013; Lee
and Young, 2013; Pastor et al., 2013; Rinn and Chang, 2012;
Smith and Meissner, 2013).
Epigenome Mapping Technologies
The unprecedented genome-wide scope and nucleotide preci-
sion with which we can now map human epigenomes was
enabled by disruptive technology advancement, namely the
application of microarrays and next-generation sequencing
(NGS). A slew of molecular biology assays previously used to
measure a single locus are now integrated with these platforms.
Powerful parallel short-read sequencing technologies have
proven increasingly high-throughput, fast, accurate, and cost-
effective at rates faster than Moore’s Law. By far, the greatest
advantage of NGS is its ability to survey the entire genome
in an unbiased and comprehensive manner. Due to this
monumental shift in assay capacity, researchers can ask if
conclusions drawn from locus-centered studies extend to other40 Cell 155, September 26, 2013 ª2013 Elsevier Inc.parts of the genome. In defiance of the traditional scientific
method emphasizing hypothesis testing, global profiling pro-
motes hypothesis-free exploration of new observations and
correlations. Overall, the accomplishments and discoveries of
the epigenomics field have hinged in large part on the iterative
inventions and improvements of technologies (Figure 1). Here,
we discuss cutting-edge epigenome mapping techniques that
integrate NGS platforms and disclose their advantages and
disadvantages.
Mapping DNA Methylation
Of the four nucleotides composing DNA, cytosine is by far the
most dynamic. Cytosine can be methylated at its 5th carbon
(5mC) and in the human genome 60%–80% of the 28 million
CpG dinucleotides are methylated (Lister et al., 2009; Ziller
et al., 2013). Stressing the importance of DNAmethylation during
development, deletion of cytosine methyltransferases res-
ponsible for de novo (DNMT3A, DNMT3B) or maintenance
(DNMT1) of methylation through cellular divisions results in em-
bryonic and neonatal lethality in mice (Li et al., 1992; Okano
et al., 1999). Detection of DNA methylation at individual loci
and with promoter-focused studies established the important
repressive roles of DNA methylation in imprinting, retrotranspo-
son silencing, and X chromosome inactivation (Bird, 2002).
Global DNA methylation technologies now measure DNA
methylation abundance at all cytosines at base resolution in
the human genome. The elucidation of complete human methyl-
omes progressed the narrow view that 5mC is only a stable
repressive mark to the view that it is an epigenetic mark that is
dynamically deposited and removed, can exist in non-CpG
sequence contexts, and is enriched at the bodies of actively tran-
scribed genes (Hellman and Chess, 2007; Lister et al., 2009).
Table 2. Major Conceptual Advances Convey the Utility of Epigenome Maps
Before Next-Gen Sequencing The Next-Gen Sequencing Era Futurea
DNA Methylation
Repressive mark at imprinted loci,
transposons, and in x chromosome inactivation
Metastable mark Comprehensive definition of epigenomic
variation across all human cell types
Found in active gene bodies Active DNA demethylation by TET family
proteins through 5hmC, 5fC, and 5caC
Define epigenomic variation in populations
Only dynamic in primordial germ cells and
during early embryogenesis; in CpG context
Non-CpG methylation exists especially in
ESCs oocytes, and adult brain
Discovering epigenetic signatures of disease
Tissue-specific methylation at distal
regulatory elements
Technology advances to enable single-cell
methylomes
Histone Modifications A deeper understanding of epigenomic
inheritabilty and reprogramming
Marks that correlate with promoters and gene
bodies
Over 130 different histone modifications
have been identified
High-throughput functional validation of
predicted enhancers
H3K9me3 is a mark of heterochromatin dentification of novel ncRNAs by promoter
and gene body chromatin signatures
Epigenome engineering
H3K27me3 is a mark of facultative
heterochromatin
Active enhancers are marked by H3K27ac
or H4K16ac
Improved computational analysis and
visualization tools
Proposal of the Histone Code Hypothesis Poised enhancers are marked by H3K4me1
alone or in combination with H3K27me3
Bivalent Promoters marked by H3K4me3/
H3K27me3
Expansion of repressive chromatin blocks
during differentiation
Unique chromatin signature of enhancers
defined as H3K4me1
Combinations of chromatin marks define
a limited number of chromatin states
Chromatin Structure
Nucleosome maps only in yeast, fly Nucleosomes mapped in the human genome
DHSs correlate with TF-binding sites and
regulatory elements
Nucleosomes are well positioned around
regulatory regions
DHSs predict enhancer-promoter pairs and
cell types affected in disease
Nuclear Architecture
Identification of chromosome territories,
LADS, and transcription factories with FISH
Identification of sub-TADs, TADs and
chromosome compartments
Few validated enhancer-promoter
interacting pairs
Chromosome-wide maps of enhancer,
promoter, and insulator interacting pairs
aText in this column refers to DNA Methylation, Histone Modifications, Chromatin Structure, and Nuclear Architecture.The DNA methylation toolkit includes three main molecular-
biology-based techniques: digestion of genomic DNA with
methyl-sensitive restriction enzymes, affinity-based enrichment
of methylated DNA fragments, and chemical conversion
methods (Bock, 2012; Laird, 2010). The choice of how to assay
DNA methylation depends on the resolution and genome
coverage needs, and both parameters ultimately dictate the
experimental cost (Figure 2). Endonuclease digestion-based
DNA methylation assays (MRE-seq, etc.) determine CpG
methylation at base resolution by digesting genomic DNA with
several methylation-sensitive enzymes. The genome-wide CpG
coverage of MRE-seq is limited by the cutting frequency of the
chosen restriction enzyme(s) and biased toward the enzyme
recognition sequences, whereas the accuracy is dependent on
complete digestion. Affinity-based enrichment assays capture
methylated fragments from sonicated DNA with an antibody
(MeDIP-seq) or a methyl-binding domain (MBD-seq) (Downet al., 2008; Serre et al., 2010). When sequencing enriched
DNA fragments, at least one cytosine is certainly methylated
but the exact site or combination of sites can not be directly
determined. Therefore, the resolution of affinity-based assays
is highly dependent on the DNA fragment size, CpG density,
and immunoprecipitation quality of the reagent. The results
of both restriction-enzyme- and affinity-based sequencing
methods are qualitative levels of enrichment rather than abso-
lute. On the other hand, because affinity- and restriction-
enzyme-based methylation assays enrich or capture methylated
DNA regions the sequencing costs are moderate.
Bisulfite sequencing is a chemical conversion method that
directly determines the methylation state of each cytosine in a
binary fashion and is widely accepted as a gold standard for
mapping DNA methylation. Treatment of genomic DNA with
sodium bisulfite chemically converts unmethylated cytosines
to uracil. After PCR, and assuming nearly complete bisulfiteCell 155, September 26, 2013 ª2013 Elsevier Inc. 41
Figure 1. Timeline of Sequencing-Based Technologies for Mapping Human Epigenomesconversion, all unmethylated cytosines become thymidines and
remaining cytosines correspond to 5mC. Initially, individual loci
were assayed from BS-treated genomic DNAwith locus-specific
PCR followed by Sanger sequencing (Clark et al., 1994). In a step
toward increasing genomic coverage, reduced representation
bisulfite sequencing (RRBS) combines restriction digestion
with bisulfite sequencing for specific interrogation of high CpG
density regions such as clusters of CpGs at promoters called
CpG islands (Meissner et al., 2005). At the pinnacle of the
genomic coverage spectrum, bisulfite treatment coupled with
whole-genome sequencing (variably referred to as MethylC-
seq, BS-seq, orWGBS) features nucleotide resolution and quan-
titative rates of methylation for all cytosines (Cokus et al., 2008;
Lister et al., 2008). Careful analysis of MethylC-seq data should
consider PCR biases due to unbalanced GC content of methyl-
ated and unmethylated fragments, mapping inefficiencies of
bisulfite-treated DNA, and estimate the bisulfite conversion
rate using a spike-in control (Krueger et al., 2012; Laird, 2010).
The DNA methylation field collectively experienced an epiph-
any upon the discovery of 5-hydroxymethylcytosine (5hmC) as
an intermediate of demethylation of 5mC to cytosine (Kriaucionis
and Heintz, 2009; Tahiliani et al., 2009). The ten-eleven translo-
cation (TET) family of proteins, TET1, TET2, and TET3, oxidize
5mC through 5hmC, 5-formylcytosine (5fC), and 5-carboxylcyto-
sine (5caC) intermediates before being replaced by cytosine via
base excision repair pathways or a yet-unidentified decarboxy-
lase (Pastor et al., 2013). As it became clear that four variants
of cytosine exist, a clarification to MethylC-seq results also
came to light. 5mC and 5hmC, but not 5fC or 5caC, are both
resistant to bisulfite conversion and therefore cannot be distin-
guished from each other in MethylC-seq data (Huang et al.,
2010; Jin et al., 2010). In order to understand the role of DNA de-
methylation, new techniques would need to be developed to
accurately differentiate cytosine methylation states.
In an exciting advancement in the field, an assortment of
methods was published for the detection of all cytosine methyl-
ation states across the genome. The first versions use antibodies
to either directly immunoprecipitate 5hmC (hMeDIP-seq) or
chemically modify 5hmC making it more immunogenic (anti-
CMS, hMe-Seal, GLIB, and JBP-1) (Ficz et al., 2011; Pastor
et al., 2011; Robertson et al., 2011; Song et al., 2011; Williams
et al., 2011). Although these methods are an important advance-42 Cell 155, September 26, 2013 ª2013 Elsevier Inc.ment, affinity-based techniques are hindered by low-resolution
and qualitative signal, as mentioned above. Last year, both
oxidative bisulfite sequencing (oxBS-seq) and TET-assisted
bisulfite sequencing (TAB-seq) were introduced as single-base
resolution methods for measuring 5hmC (Booth et al., 2012; Yu
et al., 2012). In oxBS-seq, 5hmC nucleotides are sensitized to
bisulfite treatment after a chemical reaction specifically oxidizes
all 5hmC and to 5fC. Then, DNA is successively treated with
sodium bisulfite such that remaining cytosines must originally
be 5mC. The sequencing results of oxBS-seq, therefore, accu-
rately capture 5mC levels and subtraction from MethylC-seq
data reveals true 5hmC sites. Of concern with oxBS-seq are
the successive chemical treatments that can induce DNA
damage and skew the results. The second approach, TAB-
seq, directly assays 5hmC location and abundances. First,
5hmC is tagged with a glucose molecule using the T4 bacterio-
phage enzyme beta glucosyltransferase. Next, genomic DNA
is treated with purified TET enzyme to oxidize 5mC to 5caC
while glucosylated-5hmC is protected. Finally, after bisulfite
treatment and sequencing, only 5hmC is read as cytosine, while
all unmethylated cytosines and cytosine variants are detected as
thymidine. TAB-seq’s accuracy is especially dependent on
efficient oxidation and conversion by TET, such that a bottleneck
is the tedious process of purifying catalytically active TET
enzyme (Song et al., 2012). In a final round of progress for
DNA methylation detection, methods to detect 5fC (fC-seq,
fCAB-seq, 5fC-DP-Seq) and 5caC (5caC-seq) were recently
described (Raiber et al., 2012; Shen et al., 2013; Song et al.,
2013).
Methods without enrichment steps, like MethylC-seq, oxBS-
seq, and TAB-seq, require an immense amount of sequencing
and are costly (Figure 2). In order to quantitatively measure the
methylation rate at each cytosine, high-quality single-nucleotide
resolution 5mC methylome data sets are expected to have 30X
sequencing depth. A recent study by Meissner and colleagues
finds that only 20% of CpGs are differentially methylated be-
tween 30 diverse human cell and tissue types tested. Therefore,
up to 80% of MethylC-seq data are the result of superfluous
sequencing of DNA fragments without CpGs or containing unin-
formative, constitutively methylated CpGs across 30 cell and
tissue types examined (Ziller et al., 2013). Sequencing costs
can be limited by targeted DNA methylation mapping as
Figure 2. Comparison of Human DNA Methylation Mapping
Technologies
The size of the circle is proportional to the genome-wide CpG coverage of the
technology.accomplished by bisulfite padlock probes (BSPPs) and
Illumina’s Infinium 450K BeadChIP technology (Bibikova et al.,
2011; Diep et al., 2012). Theoretically, base resolution methyl-
omes of rare cytosine variants such as 5caC should have
1,000X sequence coverage (Pastor et al., 2013). The extreme
sequencing depth is necessitated by the rarity of cytosine vari-
ants; for example, in mouse embryonic stem cells (mESCs)
5hmC accounts for about 0.1% and 5caC accounts for
0.0003% of cytosines (Ito et al., 2011; Yu et al., 2012). Unfortu-
nately, the prohibitive cost of genome-wide base resolution
human methylomes has limited the number of available data
sets, and presumably slowed progress toward novel insights.
Resolution, genomic coverage, and monetary cost serve as
interdependent considerations for generating methylome da-
tum, where one parameter cannot be changed without affecting
the others (Figure 2). Maximizing resolution and coverage while
keeping costs low, currently an unrealistic situation, may eventu-
ally be possible with innovative sequencing platforms or a yet
undiscovered alternative to bisulfite treatment. We look forward
to the democratization of nucleotide resolution DNA methylation
technologies and the resulting novel findings from a diverse
collection of methylomes.
Mapping Chromatin Modification States
Chromosomal DNA is packaged into nucleosomes with DNA
wrapped around histone octamers consisting of H2A, H2B, H3,
H4 subunits and their variants. The histone tails and globular
domains of histone proteins are subject to over 130 posttransla-
tional modifications (PTMs) and over 700 distinct histone iso-
forms have been detected in human cells (Tan et al., 2011;
Tian et al., 2012). Well-studied covalent modifications on his-
tones include methylation, acetylation, phosphorylation, and
ubiquitination. State-of-the-art mass-spectrometry-based pro-
teomic technologies unveiled many novel histone PTMs, suchas crotonylation, succinylation, malonylation, and others (Tian
et al., 2012). Histone modifications serve both activating and
silencing roles in transcription, generally by controlling the
accessibility of DNA and by serving as binding substrates that
recruit or exclude protein complexes (Kouzarides, 2007). For
example, H3K27ac is found at both active promoters and en-
hancers, H3K36me3 identifies actively transcribed gene bodies,
and H3K27me3 marks heterochromatic or repressed regions (Li
et al., 2007) (Table 3). Determining the genome-wide distribution
of a histonemark can lead to clues about its role in transcriptional
regulation and provoke follow-up mechanistic studies to further
understand the PTMs deposition, removal, and role in develop-
ment and disease.
Chromatin immunoprecipitation followed by sequencing
(ChIP-seq) maps the genome-wide binding pattern of chro-
matin-associated proteins, which includes modified histones.
To perform this method, DNA-protein complexes containing a
specific protein of interest are immunoprecipitated from cross-
linked, sonicated chromatin. DNA is purified from the enriched
pool and adaptors are ligated for subsequent PCR and
sequencing. The digital sequences of enriched DNA, called
reads, are computationally aligned to the reference genome to
define punctate peaks or broad blocks of modified histones or
protein occupancy. Since its development in 2007, researchers
have used ChIP-seq extensively to survey the genomic profiles
of histones and their modifications, TFs, DNA and histone modi-
fying enzymes, transcriptional machinery, and other chromatin-
associated proteins (Barski et al., 2007; Johnson et al., 2007;
Mikkelsen et al., 2007; Robertson et al., 2007). Furthermore,
multidimensional data sets are now available for cell lines, pri-
mary cells, tissues, and embryos from an increasing number of
species. The ENCODE and Roadmap Epigenomics Projects
have contributed enormous data repositories by performing
thousands of ChIP-seq experiments in hundreds of human cell
types.
As the number of ChIP-seq data sets began to grow exponen-
tially, lab-to-lab protocol variability threatened the quality of
results and downstream cross-study analysis. To stave off
data inconsistencies, both the ENCODE andRoadmap consortia
published optimized standard operating procedures for ChIP-
seq. Of major concern was the quality of antibodies for which
ChIP is undeniably dependent. Both consortia assessed histone
modification antibody quality using dot blot immunoassays
against histone tail peptides to ensure specific binding and
minimal cross reactivity (Egelhofer et al., 2011). The ENCODE
Project’s best practices include a rigorous two-stage antibody
validation process with a combination of immunoassays, immu-
nofluorescence patterns, and functional assays (Landt et al.,
2012). These screening methods dramatically improved the
data quality and reduced costs and lost time from failed ChIP-
seq experiments. However, the membrane-binding conditions
in immunoassays are not identical to immunoprecipitation in
solution using magnetic beads. Lamentably, the gold standard
for ChIP-grade antibody classification remains actually perform-
ing the assay itself. To this point, Bernstein and colleagues de-
signed a method called ChIP-string to screen for effective anti-
bodies against chromatin regulator proteins (Ram et al., 2011).
In this approach, multiplexedmeso-scale ChIP-seq experimentsCell 155, September 26, 2013 ª2013 Elsevier Inc. 43
Table 3. Distinctive Chromatin Features of Genomic Elements
Functional Annotation Histone Marks References
Promoters H3K4me3 Bernstein et al., 2005; Kim et al., 2005; Pokholok
et al., 2005
Bivalent/Poised Promoter H3K4me3/H3K27me3 Bernstein et al., 2006
Transcribed Gene Body H3K36me3 Barski et al., 2007
Enhancer (both active and poised) H3K4me1 Heintzman et al., 2007
Poised Developmental Enhancer H3K4me1/H3K27me3 Creyghton et al., 2010; Rada-Iglesias et al., 2011
Active Enhancer H3K4me1/H3K27ac Creyghton et al., 2010; Heintzman et al., 2009;
Rada-Iglesias et al., 2011
Polycomb Repressed Regions H3K27me3 Bernstein et al., 2006; Lee et al., 2006
Heterochromatin H3K9me3 Mikkelsen et al., 2007survey DNA enrichment at 500 representative loci using the
nCounter probe system. High-quality antibodies are distinct
from IgG patterns and the occupancy distribution correlates
with a logical set of chromatin states. Validating antibody re-
agents for enrichment specificity and robustness ensures good
quality ChIP-seq data sets with high signal to noise ratios.
Given that ChIP-seq is a mature technology, the technical
restrictions of the technique are well defined by its users. These
restrictions include the need for large amounts of starting mate-
rial, limited resolution, and the dependence on antibodies.
Improvements to ChIP-seq have been developed to address
these limitations and expand the possibilities of its use. Collect-
ing enough starting material for ChIP-seq can be challenging
because experiments typically require 1 million (histone modifi-
cations) to 5million (TFs and chromatinmodifiers) cells. Although
this is feasible when studying fast dividing cell lines, the chal-
lenge arises when studying primary cells and rare populations
such as cancer stem cells or progenitor cells. ChIP-seq samples
of 50,000 cells or less are possible with the ChIP-nano protocol
(Adli and Bernstein, 2011). Key method modifications achieve
effective chromatin fragmentation in small volumes, ensure
minimal sample handling and loss by washing samples in col-
umns, and reduce background signal. Another procedure, called
ChIP-exo, improves the limited resolution from fragmentation
heterogeneity after chromatin is prepared by sonication (Rhee
and Pugh, 2011). As its name suggests, sonicated and immuno-
precipitated DNA is treated with a 50-to-30 exonuclease to digest
DNA to the footprint of the crosslinked protein such that
sequencing results are nucleotide resolution. This type of high-
resolution protein-binding data is most beneficial for uncovering
motifs of specific binding proteins and the effect of sequence
variants on protein-binding affinity. Profiling genome-wide
DNA-protein interactions with ChIP-seq is technically chal-
lenging when studying novel proteins or protein isoforms, such
as a histone variant, that lacks a robust or specific antibody.
In this case, an obvious approach is to transiently or stably ex-
press a protein of interest (POI) with a tag or epitope that can
be readily ChIP’ed. Controls are necessary to ensure the fusion
protein’s localization is not altered by nonendogenous expres-
sion levels, protein instability, steric inherence, or other effects
of the tag itself.
A ChIP step can be added to other genomic profiling ap-
proaches for integrated epigenomic profiling. First, two ChIP44 Cell 155, September 26, 2013 ª2013 Elsevier Inc.steps in a row, or Sequential-ChIP-seq, can uncover histone
PTMs on the same molecule or chromatin-associated proteins
in the same complex. Several groups combined bisulfite
sequencing with ChIP giving rise to BisChIP-seq and ChIP-BS-
seq (Brinkman et al., 2012; Statham et al., 2012). Long-distance
DNA interactions mediated by a specific protein can be profiled
using chromatin interaction analysis by paired-end-tag
sequencing, or ChIA-PET (Fullwood et al., 2009). We anticipate
other inventive uses of ChIP technology to continue to uncover
undiscovered roles of histone modifications and histone variants
in transcriptional regulation.
Mapping of Chromatin Structures
Nucleosome Positioning
Moving up the hierarchy of genomic organization, we now look
beyond the DNA and histone modifications to the positioning
of nucleosomes along the genome. Our epigenome at its
most basic level is repeating units of 147 base pairs wrapped
1.7 times around each nucleosome with varying distances of
linker DNA between each unit. Even this extremely simplistic
model is complex because nucleosome positioning can both
inhibit and promote factor binding (Bell et al., 2011). First,
nucleosomes can be positioned to obstruct or reveal specific
DNA sequences. Second, becausemodifications on histone tails
serve as binding platforms for transcriptional regulators, nucleo-
some positioning regulates factor recruitment. And finally,
nucleosomes are suggested to inhibit transcription by slowing
progression of RNA polymerase II as it transcribes through a
gene body. From a medical perspective, it will be important to
determine the possible role of aberrant nucleosome positioning
as caused by disease-associated SNPs, insertions, deletions,
and translocations.
Our understanding of the regulation of nucleosome positioning
came from studies of smaller genomes, such as those in yeast
and fly (Jiang and Pugh, 2009). Nucleosome positioning along
DNA is influenced by favorable DNA sequence composition,
the actions of ATP-dependent nucleosome remodelers, and
strongly positioned nucleosomes (Mavrich et al., 2008; Narlikar
et al., 2013; Yuan et al., 2005). Although we understand the
main determinants of nucleosome positioning, the exact contri-
bution of each is unclear and currently under debate.
The most common method for profiling genome-wide
nucleosome positioning is microcococal nuclease digestion of
chromatin followed by high-throughput sequencing (MNase-
seq). When native, uncrosslinked chromatin is digested with
MNase, the linker DNA is cleaved while DNA wrapped around
histone octamers or bound by TFs is protected. After purifying
the DNA, approximately 150 bp fragments corresponding to
mononucleosomes are size selected on a gel and sequenced.
Given the relative size of the human genome as compared to
model organisms and that most of it is nucleosomal, mapping
nucleosome positioning in the human genome is no small feat.
Even with only 10-fold genome coverage in CD4+ T cells, it
was clear that nucleosomes are depleted at active transcrip-
tional start sites (TSSs) and enhancers with ordered positioning
radiating outward (Schones et al., 2008). In an extraordinary
sequencing effort, Gaffney et al. generated paired and single-
end MNase-seq data in seven lymphoblastoid cell lines yielding
240X coverage of a single cell type and found that 80% of the
genome has nonrandom, albeit weakly positioned nucleosomes
(Gaffney et al., 2012). MNase-seq-based studies have provided
great insights into the global distribution and dynamics of nucle-
osomes in the human genome. However, there are limitations of
these data sets to consider. First, MNase digestion at the ends of
nucleosomes is inconsistent such that exact position of nucleo-
somes can only be estimated as the center of fragments of
different lengths. The results are unfortunately not single-base
resolution. Moreover, MNase has AT sequence preferences,
and MNase-protected 150 bp fragments are inferred to be
mononucleosomes but could in fact be created by other proteins
as well (Brogaard et al., 2012).
To circumvent the weaknesses of digestion-based detection
of nucleosome positioning, Widom and colleagues used chemi-
cal modification of engineered histones to cleave DNA wrapped
around nucleosomes (Brogaard et al., 2012). In short, DNA is pre-
cisely cleaved in a reaction with hydroxyl radicals if it interacts
with amutated residue onH4whilewound around a nucleosome.
Using this method, nucleosome maps in yeast show remarkable
accuracy and consistency. Interestingly, single-base-pair reso-
lution of yeast nucleosomes reveals a 10 bp periodic sequence
preference of flexible dinucleotides throughout the 147 bases
in contact with the histone octamer. These data suggests that
the role of sequence composition in the rotation positioning of
the nucleosomes is stronger than previously appreciated. This
method could be extended to the human genome for precise,
high-resolution nucleosome positioning studies.
Another MNase-independent method for mapping nucleo-
some positioning uses DNA methyltransferase accessibility to
footprint nucleosome positions, called nucleosome occupancy
and methylome sequencing (NOMe-seq) (Kelly et al., 2012).
The unique activity of the DNA methyltransferse M.CviPI, which
methylates cytosine only in the GpC context, is exploited to re-
cord theDNA’s nucleosomal status because nucleosomal nucle-
otides are protected from methylation. Next, the DNA is bisulfite
treated to convert unmethylated cytosines to thymide. Following
sequencing, cytosines in the CpG context were originally meth-
ylated (5mC or 5hmC) and cytosines in the GpC context were
nucleosome depleted. An important advantage of NOMe-seq
is the dual epigenomic information, both nucleosome position
and DNAmethylation abundance, comes from a single molecule
rather than possibly co-occurring in a population of cells.Chromatin Accessibility
Nucleosomes are the basic repeated structural unit of the
genome and proteins that compete for DNA binding can affect
their positioning. Biochemically active regulatory elements,
including promoters, enhancers, silencers, and insulators, are
bound by sequence-specific regulatory TFs. Open chromatin is
therefore an overarching characteristic of biochemically active
genomic regions. Open chromatin can be assayed genome-
wide by DNase hypersensitivity followed by sequencing
(DNase-seq) or formaldehyde-assisted identification of regulato-
ry elements followed by sequencing (FAIRE-seq) (Boyle et al.,
2008; Giresi et al., 2007). DNase-seq takes advantage of the pro-
tection conferred by tightly wound nucleosomes from DNaseI
endonuclease digestion. Accordingly, limited digestion of
native chromatin releases nucleosome-depleted fragments.
Sequencing and mapping of these fragments identifies
DNaseI-hypersensitive sites (DHSs) corresponding to regulatory
regions. Protein and complex binding within a DHS create
6–40 bp sequences of DNaseI protection, called digital DNase
footprints, which can be called after deep sequencing of
DNase-seq libraries (Neph et al., 2012b). Beyond being DNaseI
hypersensitive, open chromatin regions are also sensitive to
shearing by sonication, and this concept is exploited by the
FAIRE-seq assay. Initially, chromatin isolated from formalde-
hyde crosslinked cells is subject to sonication. Subsequently,
free DNA unbound by proteins is isolated from the aqueous
phase following phenol-chloroform extraction. Similar to
DNase-seq, mapping the FAIRE-seq enriched fragments demar-
cate open chromatin and regulatory elements.
Myriad chromatin accessability maps are now available due to
the adoption of DNase-seq by the ENCODE Project Consortium
and Roadmap Epigenomics Program. In total, these consortia
produced hundreds of maps encompassing 349 cell types
including pluripotent stem cells, stem cell progenitors, cultured
primary cells, and human fetal tissue from various types and
gestational stages (Maurano et al., 2012). Meta-analysis of these
data sets determined DHSs span 2.1% of the genome per cell
type on average, and, impressively, all 4,000,000 sites collec-
tively cover 40% of the genome (Maurano et al., 2012). Map-
ping nucleosome-depleted chromatin is a comprehensive way
to identify the global catalog of regulatory elements and factor-
binding sites without specific antibodies or prior knowledge of
cell-type-specific transcriptional regulators.
Mapping of Higher Order Chromatin Architecture
Lower-order chromatin structures such as the 11 nm fiber, also
called ‘‘beads on a string,’’ are followed by higher-order struc-
tures like the 30 nm fiber and 700 nmmitotic chromosomes (Fel-
senfeld and Groudine, 2003). Incidentally, genome compaction
brings regions that are linearly distant via short and long-range
chromatin interactions. Mapping the 3D structure of the nucleus
is important because, like histone marks and chromatin accessi-
bility, chromosome conformations influence mammalian gene
regulation. For example, chromatin in close proximity to the lam-
ina of the inner nuclear membrane, or lamin-associated domains
(LADs), tends to be heterochromatic and transcriptionally
repressed (Akhtar et al., 2013; Guelen et al., 2008). In contrast,
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promoters, called transcription factories, correlate with robust
gene expression (Brown et al., 2008). Historically, fluorescentmi-
croscopy imaging, though limited by resolution and throughput,
has served as the gold standard for observing nuclear structure.
In fact, both LADs and transcription factories were discovered in
this fashion.
A paradigm shift from FISH-basedmethods towardmeasuring
physical DNA interactions has revolutionized our ability to
broadly map nuclear architecture. The introduction of chromo-
some conformation capture (3C) by Dekker and colleagues pro-
vided an alternative to mapping distances between two loci
(Dekker et al., 2002). Succinctly, chromatin from formaldehyde
crosslinked cells is digested with a restriction enzyme followed
by DNA ligation under extremely dilute conditions to favor joining
of ends in close proximity to each other. After reversal of cross-
links and DNA purification, the ligation frequency between two
restriction fragments, measured by qPCR, indicates their inter-
action frequency. Such interaction frequency is generally related
to the spatial distance, though this relationship could be com-
plex, nonlinear, and influenced by chromatin accessibility (Dek-
ker et al., 2013; Williamson et al., 2012).
Differing in the number of loci tested and selection of loci, the
suite of 3C-based assays include 3C, circular chromosome
conformation capture (4C), chromosome conformation capture
carbon copy (5C), tethered conformation capture (TCC), ChIA-
PET, and Hi-C (reviewed by de Wit and de Laat, 2012; Sajan
and Hawkins, 2012; van Steensel and Dekker, 2010). Of these,
3C and 5C are locus-centric methods, meaning the assayed
regions are selected a priori. Sequence-specific primers are
designed for each locus of interest, for instance promoters
or cis-regulatory elements. As stated previously, 3C measures
the interaction frequency of one locus with another (one-to-
one), between an anchor and a bait sequence, by qPCR. 5C
attains higher throughput capacity by utilizing thousands of
anchor and bait primers that can span an entire chromosome
(many-to-many) (Dostie et al., 2006). The 4C method measures
the genome-wide interaction frequency of a single anchor site.
Inverse PCR of ligated and circularized interacting DNA
fragments detects all interacting loci (one-to-all) (Zhao et al.,
2006).
Hi-C measures the entire genome’s interaction frequency
with itself as a large matrix without enrichment for specific loci
(all-to-all) (Lieberman-Aiden et al., 2009). The key innovation of
Hi-C is the ability to enrich for ligation junctions of interacting
fragments. After digestion of crosslinked chromatin with a
6-base cutter, the overhang ends are filled in with a biotinylated
base. As with all 3C-based assays, the DNA fragments are
extremely dilute in the presence of ligase to promote intramolec-
ular ligation events. The ligated sample is sonicated and a
streptavidin pulldown captures all junctions of interacting DNA
fragments, which are then sequenced. Hi-C interaction signal-
to-noise ratio is dependent on the rate of intramolecular ligation
events. TCC, a Hi-C variation, performs the ligation step on the
streptavidin bead to promote these favorable ligation events
(Kalhor et al., 2012). ChIA-PET is another variation of Hi-C that
features an immunoprecipitation step to map DNA interactions
involving a POI (Fullwood et al., 2009). This approach has been
useful for understanding proteins involved in nuclear organiza-46 Cell 155, September 26, 2013 ª2013 Elsevier Inc.tion such as TFs, RNA polymerase, CTCF, and cohesin (Demare
et al., 2013; Fullwood et al., 2009; Handoko et al., 2011; Li et al.,
2012).
Due to its unbiased genome-wide scale, Hi-C promotes the
discovery of novel interactions and structures. The size or level
of nuclear architecture assayed with Hi-C is dependent on
experimental resolution, which in turn is limited by both restric-
tion enzyme cutting frequency and sequencing depth. At 1 Mb
resolution, Dekker and colleagues defined higher-order chromo-
some compartments that average about 5 Mb in size across the
genome (Lieberman-Aiden et al., 2009). Termed A and B
compartments, these sequentially interchanging structures
correlate with euchromatic and heterochromatic genomic
regions, respectively, in a cell-type-specific manner. With
increased sequencing depth, we attained 40 kb resolution Hi-C
interaction data. In this way, our lab identified cell-type and spe-
cies invariant 1 Mb regions of high local interaction frequency,
called topological domains or topologically associated domains
(TADs), separated by noninteracting boundary elements (Dixon
et al., 2012). Boundary regions correlate with the limits of hetero-
chromatin blocks and are enriched for CTCF-binding sites,
housekeeping genes, and certain transposon elements. With
deeper sequencing and improved data analysis algorithms for
Hi-C data, it may be possible to reach fragment length resolution
or about 4 kb when using a 6-base cutter.
What has become clear using microscopy and now 3C-based
assays is a gradient or spectrum of DNA folding architecture
(Figure 3). These interactions start as one-to-one looping of
regulatory elements including enhancers, promoters, and insu-
lators. A collection of these interactions flanked by boundary re-
gions form local interacting neighborhoods or TADs (Dixon et al.,
2012; Nora et al., 2012). Using 5C, sub-TADs were recently
recognized as finer resolution segments of TADs that can be
cell-type-specific (Phillips-Cremins et al., 2013). Together
many TADs contribute to a larger chromosome compartment
and, finally, to an entire chromosome territory (Lieberman-Aiden
et al., 2009). In summary, the advent of 3C technologies has re-
vealed novel and complex layers of genome annotation. Many
questions remain regarding how nuclear architecture is regu-
lated and how it mechanistically influences transcription, cellular
identity, and possibly disease.
Utility of Epigenome Maps
In addition to rapid development of new epigenome mapping
technologies, another important factor fueling the remarkable
progress of epigenomics is the formation of many research
consortia worldwide. Most notable among these consortia are
the US Roadmap Epigenome Project, the ENCODE Project,
and the International Human Epigenome Consortium (IHEC) (Ta-
ble 1). Modeling after the hugely successful Human Genome
Project (Lander, 2011), these consortia standardized experi-
mental protocols, recommended data analysis procedures,
and most importantly, publicly released large amounts of data
sets prior to publication. Consequently the number of epige-
nome maps generated has grown exponentially, from a handful
in early 2007 to several thousand as of today. As detailed below,
thesemaps have proved to be most valuable in annotation of the
transcription units, cis-regulatory sequences, and other genomic
Figure 3. Hierarchical Principles of Nuclear
Organizationfeatures in the human genome. Integrative analysis of epi-
genomic maps has facilitated study of the gene regulatory
programs involved in pluripotency, adipogenesis, and cardio-
myocyte differentiation (Gifford et al., 2013; Hawkins et al.,
2010; Mikkelsen et al., 2010; Rada-Iglesias et al., 2012; Wam-
stad et al., 2012; Xie et al., 2013b; Zhu et al., 2013). Further, com-
parison with genome-wide association studies (GWAS) revealed
enrichment of disease-associated sequence variants in putative
cis-regulatory elements, providing insights into the pathogenesis
of many common human diseases.
Annotation of cis-Regulatory Elements from Chromatin
Profiles
A major challenge confronting biomedical researchers is the
absence of functional annotation of the human genome, where
the vast majority (98.5%) do not code for proteins yet harbor
most of the disease-associated genetic variations. Several types
of functional sequences are known to exist in the noncoding
parts of the human genome including cis-regulatory elements.
These sequences, including promoters, enhancers, and insula-
tors, govern gene expression by recruiting sequence-specific
TFs that modulate local chromatin structure and assembly of
transcriptional machinery. Because these functional DNAs lack
consistent and recognizable sequence features, their identifica-
tion and characterization had until recently been quite difficult.
Epigenome maps have proven to be a powerful tool for anno-
tating the functional features in the human genome. This is
possible because several classes of DNA elements are associ-
ated with characteristic histone modifications (Table 3). Early
studies revealed that H3K4me3 predominantly associates with
promoters and H3K36me3 with gene bodies. Thus, new gene
units could be identified with the use of chromatin profiles.
Indeed, this strategy led to the identification of several thou-
sands of long noncoding intergenic RNA genes (lincRNA) (Gutt-Cell 155, Sman et al., 2009). Similarly, our lab
showed that transcriptional enhancers
are characterized by the presence of
H3K4me1 but not H3K4me3, a combina-
tion that accurately predicted tens of
thousands of new enhancers in the hu-
man genome (Heintzman and Ren,
2009; Heintzman et al., 2007). Despite
initial hesitation that this signature may
not universally demarcate enhancers in
different cell types or in more than one
species, H3K4me1 marks enhancers in
all tested cell types from human to zebra-
fish to fly (Aday et al., 2011; Heintzman
and Ren, 2009; Roy, et al., 2010). Impor-
tantly, as researchers have annotated
enhancers in many human cell types,
they have realized that cell-type speci-
ficity is a persistent feature of enhancers
and is consistent with their role in determining cellular identity.
Other general properties of enhancers that are validated
genome-wide include DNaseI hypersensitivity, combinatorial
TF binding, H3.3 and H2A.Z histone variant enrichment, bound
RNA Pol II, and RNA production (enhancer RNAs or eRNAs)
(Buecker and Wysocka, 2012). Combinations of these features
along with H3K4me1 allow refined and highly accurate
genome-wide enhancer prediction (Rajagopal et al., 2013).
Initially, chromatin states in two human cell lines, HeLa cells
and K562 cells, were mapped and used to predict 55,000 candi-
date enhancers in the human genome (Heintzman et al., 2009).
This study demonstrated that chromatin modifications at en-
hancers, in particular H3K4me1 and H3K27ac, are cell-type-
specific and correlate with cell-type-specific gene expression
throughout the genome, suggesting a potentially critical role
for enhancers in lineage-specific gene regulation. Subsequent
studies confirmed this result in additional cell types. Rada-Iglesia
and colleagues characterized the chromatin modification pro-
files in the human embryonic stem cells (hESC) and identified
approximately 7,000 candidate enhancers featuring binding of
TFs, presence of H3K4me1mark, and depletion of nucleosomes
(Rada-Iglesias et al., 2011). Interestingly, they also classified
these enhancers into ‘‘active enhancers’’ and ‘‘poised en-
hancers,’’ which differ mainly in the presence or absence of
H3K27ac mark. Active enhancers are near genes expressed in
hESCs, while poised enhancers are next to genes inactive in
hESC but turned on during differentiation (Rada-Iglesias et al.,
2011). Independently, Creyghton and colleagues, by examining
the chromatin modification patterns in the mESCs and several
differentiated mouse cell types, also found that H3K27ac can
distinguish the active enhancers from poised ones (Creyghton
et al., 2010). While tens of thousands of enhancers are typically
marked in a cell type, a small subset of enhancers (<1%) form
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mediator, and master transcription factor binding (Whyte et al.,
2013). These ‘‘superenhancers’’ are posited to regulate key
genes important for cell identity. For example, in mESCs super-
enhancers are associated with genes necessary for pluripotency
and in myotubes they are associated with skeletal muscle devel-
opment. Lastly, enhancers are turned off or ‘‘decommissioned’’
by the removal of H3K4me1 and H3K27ac marks when they no
longer pertain to the cellular state. For example, enhancers
that control genes important for pluripotency must be decom-
missioned for proper differentiation (Whyte et al., 2012). By
profiling key chromatin marks in different cell types, researchers
can now annotate the location and activity state of regulatory
elements across the genome to define a cell-type’s regulome.
Extending the idea that chromatin modification patterns are
associated with different functional sequences, a comprehen-
sive epigenomic study of nine human cell lines showed that the
human genome could be segmented into regions carrying one
of 15 different combinations of chromatin modification marks
in each cell type (Ernst et al., 2011). The authors implemented
a multivariate hidden Markov model called ChromHMM to un-
biasedly infer these chromatin states from the chromatin modifi-
cation profiles. This approach found that each chromatin state
corresponds to a specific category of genomic features,
including active or poised promoters, enhancers, insulators,
and silenced domains (Table 3). Similar results have been ob-
tained with other machine-learning algorithms (Hoffman et al.,
2013; Won et al., 2013). More recently, the ENCODE Consortium
profiled the chromatin modification state in 46 human cell types,
and found that asmuch as 56%of the genome is associatedwith
specific histone modification patterns indicative of biochemical
activities (ENCODE Project Consortium, et al., 2012). Ongoing
studies from large epigenome mapping consortia such as the
NIH Epigenome Roadmap consortium are certain to enhance
human genome annotation even further (Bernstein et al., 2010).
Annotation of Long-Range Chromatin Interactions
Rather than the regulome simply being a collection of elements,
it must ultimately link together enhancers, insulators, promoters,
and other features in three-dimensional space. Epigenomic
maps can annotate cell-type-specific long-distance interactions
between regulatory elements using two approaches. First, long-
range looping can be mapped by physical interaction of distant
DNA loci with 3C-based assays. Considering their capabilities,
5C and ChIA-PET currently provide the best balance of resolu-
tion and reasonable coverage in the human genome for this pur-
pose (Dekker et al., 2013; Smallwood andRen, 2013). Several 5C
and ChIA-PET data sets exist that are valuable for identifying in-
teractions in selected human cell types, but diverse interaction
maps are not yet available. The second method correlates regu-
latory elements and target promoters across many cells types to
computationally infer pairs that regulate and likely interact with
each other. These in silico predictions require the annotation of
cell-type-specific enhancers and active promoters with chro-
matin signatures, DHSs, and expression profiles (Ernst et al.,
2011; Sheffield et al., 2013; Shen et al., 2012; Thurman et al.,
2012). A clear advantage of the correlative approach is the
necessary data in hundreds of cell types had already been pro-
duced by epigenomic consortia. For example, Thurman et al.48 Cell 155, September 26, 2013 ª2013 Elsevier Inc.defined almost 600,000 regulatory pairs from 79 cell types by
correlating ENCODE DNase-seq and RNA-seq data (Thurman
et al., 2012). Some of the predicted interaction correlations
defined by this approach were validated by both 3C and ChIA-
PET but more extensive cross-validation is necessary.
Furthermore, such results are limited to enhancer-promoter
communication and cannot address the role of insulators or
novel interacting regions.
Although these two approaches use different concepts to
define chromatin interactions, they independently come to
similar conclusions about nuclear architecture. The main theme
is consistent with the role of enhancers in the determination of
cellular identity: enhancer-promoter interactions are cell-type-
specific (Sanyal et al., 2012; Shen et al., 2012). As previously
suggested from single-locus studies, enhancers target pro-
moters at long distances and do not always target the nearest
gene (Ong and Corces, 2011). This is confirmed by a broader
study using 5C analysis of 1% of the human genome in three
cell types that determined that 50% of distal regulatory ele-
ments interact with the closest active gene (Sanyal et al.,
2012). Surprisingly, enhancers and promoters can interact pro-
miscuously withmore than one element indicating a complicated
web of transcriptional regulation (Sanyal et al., 2012; Shen et al.,
2012; Thurman et al., 2012). In fact, Thurman et al. used a correl-
ative approach and found half of TSSs regulate ten or more distal
sites and half of putative enhancers regulate more than one
TSS (Thurman et al., 2012). 5C physical interaction data also
confirms 49% of TSSs interact with more than one distal site
but finds only 10% of enhancers interacting with more than
one promoter (Sanyal et al., 2012). Another concept challenged
by interactome annotations, is the classic definition of CTCF-
bound insulators as having an enhancer-blocking function to
limit the range of targeted enhancer activation (Phillips and Cor-
ces, 2009). Notably, enhancer-promoter interactions often span
hundreds of kilobases surpassing one or more CTCF sites
(Demare et al., 2013; Sanyal et al., 2012). 5C analysis predicts
that almost 60% of all interactions skip a cobound CTCF/
cohesin locus (Sanyal et al., 2012). Another unexpected result
is frequent insulator interactions with promoters and enhancers
suggesting a possible role for CTCF in transcriptional activation
(Demare et al., 2013; Handoko et al., 2011; Sanyal et al., 2012).
Finally, there is an emerging role of CTCF and cohesin cobound
regulatory elements in long-range, constitutive DNA interactions
in contrast to cohesin and mediator cobound regions that facili-
tate short range, cell-type-specific enhancer-promoter interac-
tions (Demare et al., 2013; Phillips-Cremins et al., 2013; Sanyal
et al., 2012).
On the whole, great progress has been made toward under-
standing how chromatin and nuclear organization jointly regulate
global gene expression patterns. Still, it remains to be deter-
mined how up to 20 enhancers choose to target a particular pro-
moter, what the functional consequence is for a promoter to be
activated by more than once enhancer, and if these results are
merely an artifact of averaging interactions and epigenetic
maps over a population of cells. Evidence that enhancer interac-
tions frequently bypass insulators and that CTCF can loop to
transcriptional start sites suggests we must refine our under-
standing of CTCF-bound insulators. Certainly the conclusions
from these epigenomic studies will encourage mechanistic
studies to uncover the details of transcriptional regulation by
long-range interactions. Continuation of this work at high resolu-
tion and in many cell types will progress the dimensions of chro-
matin maps from a linear chart to a three-dimensional model of
genomic annotation.
Dynamic Chromatin Landscapes during Human
Development
Advances in the robustness, throughput, and accuracy of epige-
nomic technologies over the past decade have co-occurred with
a revolution in stem cell biology and regenerative medicine.
The first completed epigenomes documented the features of
cultured, immortalized or cancerous cell lines. Although this
enabled correlation of epigenomic features with genomic ele-
ments, the resulting epigenomic landscapes were a static
view. Now that lineage-specific differentiation protocols produce
populations of cells with increasing purity, it is possible to study
epigenomic dynamics during development. Such studies give
insight into how cell state transitions are influenced by chromatin
states at promoters and enhancers, DNA methylation dynamics
at enhancers, and the expansion of repressive domains. Finally,
using chromatin signatures to define lineage-specific enhancers
can lead to models of TF networks that regulate cell-type spec-
ification.
Unique chromatin signatures mark promoters and enhancers
in pluripotent cells. Some promoters in ESCs are bivalent or
comarked with active and repressive histone marks. Sequential
ChIP confirmed the presence of both H3K4me3 and H3K27me3
on the same DNA molecule or promoter allele (Bernstein et al.,
2006). Due to polycomb-mediated silencing, bivalent genes are
not expressed and specifically mark developmental genes that
are activated in downstream cell states and are ‘‘poised’’ in
ESCs. Consistent with this idea, differentiation of hESCs into
endoderm, mesoderm, and ectoderm lineages resolves 85%
of bivalent promoters into monovalent states in a lineage-spe-
cific manner (Gifford et al., 2013). H3K4me1/H3K27me3 marked
poised enhancers are a special class found mostly in ESCs and
tend to regulate bivalent promoters of developmental genes
(Rada-Iglesias et al., 2011). Chromatin state maps can have
more informative power than expression data alone, because
they identify both active genes and poised genomic elements
that foreshadow a cell type’s differentiation potential.
DNA methylation can also be informative for identifying en-
hancers and classifying their activity. Quantitative comparisons
of the first human methylomes in hESCs and fibroblasts indi-
cated regions with dynamic DNA methylation levels. A region
that is relatively hypermethylated in one cell type and hypome-
thylated in another is called a differentially methylated region
(DMR) (Lister et al., 2009). DMRs are enriched at regulatory ele-
ments as evidenced by their overlap with DNaseI sites, TF-bind-
ing sites, and enhancer chromatin marks (Hon et al., 2013; Ji
et al., 2010; Ziller et al., 2013). Active enhancers correlate with
the hypomethylated DMR state, also called low-methylated re-
gions (LMRs), and the formation and maintenance of LMRs is
dependent on TF binding (Stadler et al., 2011). However,
whether the depletion of methylation upon TF binding occurs
passively during cell cycles or through active demethylation isstill unclear. Recently generated methylomes of cytosine vari-
ants find 5hmC, 5fC, and 5caC enriched at enhancers in ESCs
suggesting the latter is possible (Pastor et al., 2011; Shen
et al., 2013; Szulwach et al., 2011; Yu et al., 2012). Even inactive
enhancers can be identified by hypomethylation. We recently
discovered ‘‘vestigal enhancers,’’ defined as regions depleted
of DNA methylation and enhancer chromatin marks in adult tis-
sues but which exhibit enhancer activity earlier in development
(Hon et al., 2013). These results suggest that the methylome re-
tains a memory of its previous cellular identities, although how
and why is still unclear. Overall, dynamic DNA methylation pat-
terns at enhancers provide yet another epigenetic feature for
their annotation. In fact, unexpected regions of hypomethylation
in transposable elements helped to annotate these regions as
tissues-specific enhancers (Xie et al., 2013a).
Cellular differentiation during development is characterized by
gradual expansion of repressed domains. In ESCs, H3K27me3 is
distributed across 8% of the genome and is most commonly
observed at bivalent promoters of developmental genes (Zhu
et al., 2013). First observed in IMR90 fibroblasts but since
confirmed in many differentiated cell types, H3K27me3 peaks
spread from bivalent promoters in ESCs to form large blocks
covering up to 40% of the genome in differentiated cells (Haw-
kins et al., 2010; Zhu et al., 2013). These large repressed regions
specifically span developmental genes, and presumably func-
tion to silence genes that do not pertain to the specified lineage.
Correspondingly, chromatin accessibility at regulatory DNA is
progressively lost during differentiation (Stergachis et al.,
2013). The epigenome of ESCs is uniquely open and accessible,
which is consistent with the role of these cells as pluripotent pro-
genitors of all three germ layers. It is now clear that during differ-
entiation and development, the epigenome is progressively
restricted like its plasticity potential.
Another major utility of epigenomic studies is the ability to
identify cell-state- or stage-specific master regulators and
construct transcriptional networks. DNase-seq-based methods
are useful for mapping all TF-binding sites genome-wide in one
assay. DNase footprint analysis in 41 human cell types from
ESCs to primary adult cells identified 45 million footprints and
subsequent de novo motif analysis discerned over 600 unique
motifs (Neph et al., 2012b). This set of motifs recovered 90%
of the TRANSFAC, JASPAR, and UniPROBE motif database en-
tries. However, nearly half of the motifs found in this study are
novel and bound by an unknown protein indicating there is a sub-
stantial amount of work to be done to have a complete under-
standing of sequence-dependent transcriptional regulators.
Similar to this approach, master transcriptional regulators can
be identified by annotating putative enhancers using histone
modification signatures followed by motif analysis of these
regions. In this way, novel master regulators of human neural
crest (NR2F1), cardiac development (Meis2), and adipogenesis
(PLZF) have been successfully identified (Mikkelsen et al.,
2010; Paige et al., 2012; Rada-Iglesias et al., 2012). Enhancer-
driven regulatory networks can be constructed by correlating
TF expression data with motif analysis at putative enhancers
as predicted by histone marks or open chromatin (Ernst et al.,
2011; Neph et al., 2012a). Alternatively, TF networks can be
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characterized the binding patterns of 119 TFs in five cell lines by
ChIP-seq that yielded ordered predictions of TF hierarchies,
rules of combinatorial TF binding, and TF-binding preferences
for distal or proximal sites (Gerstein et al., 2012). However with
over 1,000 TFs and many cell types still not assayed, the
complexity of experimentally and computationally generated
transcription factor regulatory networks will increase and re-
quires further investigation.
Understanding Disease Variants with Epigenomics
The combination of data from the Human Genome Project and
International HapMap Project enabled geneticists to study poly-
genic traits and diseases usingGWAS (Frazer et al., 2009). Inves-
tigating the genetic basis of common diseases is possible by
testing for variants that significantly associate with cases over
controls in a population. GWAS are now a common tool in ge-
netic epidemiology with over 1,600 studies published associ-
ating 11,000+ SNPs with hundreds of distinct diseases and traits
(Hindorff andMacArthur, 2013). It is often difficult when interpret-
ing GWAS results to identify the functional variant(s) underlying
an association. The difficulty arises from the fact that a SNP
associated with a particular phenotype may itself be the func-
tional variant directly causing or contributing to the phenotype,
or it may simply be in linkage disequilibrium (LD) with the func-
tional variant. Traditional GWAS alone cannot differentiate
between these two scenarios. Moreover, even after identifying
a true functional variant, it can be very difficult to determine the
molecular mechanism by which that variant alters genome func-
tion and contributes to disease. For example, 93% of SNPs
associated with human phenotypes by GWAS are located
outside of protein coding regions (Maurano et al, 2012). This
finding highlights the need for annotation of the vast noncoding
sequence of the human genome. Epigenomic maps are likely
to play a major role in identifying specific functional variants
that cause or contribute to human disease.
Assimilation of GWAS and epigenomic data can give clues
about the involvement of regulatory elements and their target
genes in the pathogenesis of common disease. Annotating en-
hancers by their chromatin state in nine cell types, Ernst et al.
found that disease-associated SNPs are enriched within cell-
type-specific enhancers from the appropriate disease cell type
(Ernst et al., 2011). By correlating the locations of over 5,000 non-
coding common disease-associated SNPs with almost 4 million
DHSs from hundreds of cell types, Maurano et al. found 40% of
GWAS SNPS fall within these regions (Maurano et al., 2012). Due
to the cell-type specific property of regulatory elements, correla-
tion of all GWAS SNPs in DHSs from a specific disease can
facilitate de novo prediction of pathogenic tissues. Using this
approach, GWAS SNPs associated with Crohn’s disease are en-
riched in the cell-type specific DHSs of TH17 and TH1 cells, and
both of these cell types have been independently associated
with this disease (Maurano et al., 2012).
Variants can affect both local open chromatin and gene
expression and these loci are called DNaseI sensitivity quantita-
tive trait loci (dsQTLs) (Degner et al., 2012). Identification of
dsQTLs in haplotyped lymphoblastoid cells from 70 individuals
found dsQTLs frequently fall within TF-binding sites, affect
nucleosome positioning as determined by MNase-seq, and50 Cell 155, September 26, 2013 ª2013 Elsevier Inc.overlap with GWAS disease-associated SNPs (Degner et al.,
2012; Gaffney et al., 2012). Interestingly 80% of dsQTLs lie
in chromatin regions previously predicted to be functional in
lymphoblastoid cell lines by epigenetic marks, including 41%
in predicted enhancers, suggesting they may be the functional
variant.
Reference epigenomes in diverse tissues and the annotation
of millions of putative enhancers can help researchers make
hypotheses about which SNPs in LD with GWAS SNPs may
contribute to disease. Following up GWAS studies by genotyp-
ing regulatory elements around GWAS SNPs may more defini-
tively identify functional SNPs. Importantly, disease-associated
SNPs that reside in putative regulatory elements must be func-
tionally validated. SNPs in enhancers may affect their activity
by disrupting TF binding, coactivator recruitment, looping inter-
actions with target promoters, or transcription of the target pro-
moter. To this end, each of these possible outcomes can be
tested with traditional approaches such as reporter assays, gel
shift assays, and allele-specific ChIP. In addition, emerging tech-
nologies such as TALENs, CRISPR/Cas9, 3C-based technolo-
gies, and new massively parallel reporter assays promise to
vastly improve the rigor and throughput with which we can test
these hypotheses (Melnikov et al., 2012; Patwardhan et al.,
2012).
The Road Ahead
Six decades ago, Watson and Crick put forward a model of DNA
double helix structure to elucidate how genetic information is
faithfully copied and propagated during cell division (Watson
and Crick, 1953). Several years later, Crick famously proposed
the ‘‘central dogma’’ to describe how information in the DNA
sequence is relayed to other biomolecules such as RNA and pro-
teins to sustain a cell’s biological activities (Crick, 1970). Now,
with the human genome completely mapped, we face the daunt-
ing task to decipher the information contained in this genetic
blueprint. Twelve years ago, when the human genome was first
sequenced, only 1.5% of the genome could be annotated as
protein coding, whereas the rest of the genome was thought to
be mostly ‘‘junk’’ (Lander et al., 2001; Venter et al., 2001). Now,
with the help of many epigenome maps, nearly half of the
genome is predicted to carry specific biochemical activities
and potential regulatory functions (ENCODE Project Con-
sortium, et al., 2012). It is conceivable that in the near future
the human genome will be completely annotated, with the cata-
log of transcription units and their transcriptional regulatory se-
quences fully mapped.
However, to reach this goal a couple of technical issues should
be resolved. First, current approaches to epigenomic analysis
still demand a large number of cells, limiting the cell types and
developmental stages that can be examined. Robust nanoscale
techniques for chromatin modification profiling, methylcytosine
detection or chromatin accessibility mapping will be necessary
to cover the full spectrum of cellular states. A few nanoscale
ChIP-seq, whole-genome bisulfite sequencing methods have
been reported, enabling epigenomic analysis of rare cell popula-
tions such as the germ cells (Adey and Shendure, 2012; Adli and
Bernstein, 2011; Ng et al., 2013). We expect that the application
of these methods to the rare cell types and to embryonic stages
will significantly broaden our knowledge of the dynamic human
epigenome, and facilitate the discovery of additional cell-type-
specific regulatory elements and transcription units. Second, a
lot of the epigenome maps currently available are from tissues
consisting of heterogeneous cell populations, and do not accu-
rately reflect the epigenomic state of a specific cell type. Today,
to isolate individual cell types from a tissue in large quantity for
epigenomic analysis by FACS is challenging. With the advance
in nanoscale epigenomic analysis technique, it will likely be
routine to obtain cell types in small quantity without affecting
their cellular state and produce epigenome maps for specific
cell populations in a tissue type. Eventually, the solution will likely
be single-cell epigenome analysis techniques. Currently, it is not
yet possible to profile the chromatin state or DNA methylation
status of a single cell, but this could become a reality with further
development of single-molecule techniques such as SCAN (sin-
gle chromatin molecule analysis in nanochannels) (Murphy et al.,
2013) or SMRT (single-molecule, real-time) sequencing (Clarke
et al., 2009; Flusberg et al., 2010).
Ultimately, to truly understand how the genome programs
human development and how certain sequence variants cause
human disease, we ought to be able to predict from the
sequence when and at what level a gene is expressed in different
cell types. To achieve this goal, we need to overcome substantial
challenges in two areas. First, wemust gain a better understand-
ing of the functional relationships between DNA methylation,
chromatin modification state, or higher order chromatin struc-
ture and gene regulation. Epigenomic studies have established
correlations between DNA hypomethylation, certain chromatin
modification signature, and chromatin structure at cis-regulatory
elements such as enhancers and promoters, but to determine
whether an epigenetic state is necessary for transcription or
merely coincidental will require additional mechanistic studies.
To this end, new technologies are required to allowmanipulation
of the epigenetic state of specific loci. The recent development
of TALE factors and CRISPR/Cas9 as a way to target histone
modification enzymes or DNA methyltransferases to specific
genomic sites is a great example (Gaj et al., 2013; Ramalingam
et al., 2013; Wang et al., 2013). Second, we need to better define
the target genes of the distal regulatory elements such as en-
hancers. This is a challenge because many enhancers are
located hundreds and thousands of base-pairs away from their
target genes, and it is not infrequent that an enhancer and its
target gene are separated by other irrelevant genes (Smallwood
andRen, 2013). Techniques such asChIA-PET, 4C, 5C, andHi-C
have been invented to identify looping interactions between en-
hancers and target promoters (de Wit et al., 2013; Li et al., 2012;
Sanyal et al., 2012; Wei et al., 2013). However, it is currently un-
clear whether mere spatial proximity is sufficient for functional
regulation. Thus, mapping physical interactions alone is unlikely
to be adequate to resolve the target genes for enhancers. An
alternative, complementary approach defines target genes for
an enhancer by searching for nearby genes sharing similar chro-
matin state or accessibility across diverse cell types (Ernst et al.,
2011; Shen et al., 2012; Thurman et al., 2012). Despite its
simplicity, this approach does not work particularly well when
a gene is regulated by multiple tissue-specific enhancers in
different tissues. A hybrid approach combining both spatialproximity and chromatin state information will likely more accu-
rately define the target genes for enhancers.
In summary, the last few years have witnessed an explosion of
the epigenomic field. Thousands of epigenome maps from hun-
dreds of human cell or tissue types have been produced, adding
crucial insights into the second dimension of the genomic
sequence. Although these human epigenomes have illuminated
potentially functional elements in the genome and improved our
understanding of the human developmental programs, it is also
clear that much more remains to be explored. Better character-
ization of epigenome variations in human populations and in
patients will be critical for us to fully appreciate the epigenetic
factors in human health and disease etiology. Indeed, projects
are already underway to profile thousands more epigenomes
from both healthy and diseased individuals (American Asso-
ciation for Cancer Research Human Epigenome Task Force; Eu-
ropean Union, Network of Excellence, Scientific Advisory Board,
2008; Bernstein et al., 2010). We anticipate an even greater
revolution in our understanding of the human epigenome in the
coming years.
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